secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001558370-23-002239
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics reports Q4 2022 net loss of $53M; launches BRIUMVI for RMS
--------------------------------------------------------------------------

- Net loss of $53.0M for Q4 2022, compared to $93.3M loss in Q4 2021; full year net loss $198.3M vs $348.1M.
- Product revenue net $2.6M for full year 2022 from UKONIQ (withdrawn May 2022); no BRIUMVI revenue yet.
- Cash and investments $174.1M at Dec 31, 2022; plus $45M available under term loan; runway into mid-2024.
- FDA approved BRIUMVI for RMS in 2022; commercial launch began early 2023; early feedback encouraging.
- R&D expense decreased to $29.6M in Q4 2022 from $62.6M in Q4 2021; SG&A decreased to $22.5M from $32.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837023002239/0001558370-23-002239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837023002239/tgtx-20230228x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer